Research
Parkinson's Disease and other movement disorders
Hope through research
The USF Health Byrd Parkinson's Disease & Movement Disorders Center evaluates and develops new medications and surgical procedures for Parkinson's Disease. Under Dr. Hauser's leadership, we conduct multiple independent and sponsored studies, pioneering advancements in treatment through research and innovation.
PPMI
Brief summary: The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Status: Recruiting (by cohort - contact our Center for details ) - For more information, review the study record:
https://clinicaltrials.gov/study/NCT04477785?term=robert%20hauser&rank=9
STEM PD
SNS-PD-002Brief summary: This is a double-blinded, controlled, randomized clinical trial (RCT) to establish the safety and efficacy of a non-invasive neuromodulation device for treating symptoms associated with Parkinson's disease.
Status: Active, not recruiting
https://clinicaltrials.gov/study/NCT04797611?term=SNS-PD-002&rank=1&limit=10
Padova
ID: NCT04777331Brief summary: A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA)
Status: Active, not recruiting
https://clinicaltrials.gov/study/NCT04777331?tab=results
M20-098
ID: NCT04750226Brief summary: Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
Status: Active, not recruiting
LUMA
ID: NCT05348785Brief summary: A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 (LUMA)
Status: Recruiting - For more information, review the study record:
https://clinicaltrials.gov/study/NCT05348785
Pasadena
ID: NCT03100149Brief summary: This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline.
Status: Active, not recruiting - For more information, review the study record:
Patagonia
JZP 385-202Brief summary: A study of suvecaltamide in adults with moderate to severe residual tremor in Parkinson’s Disease
Status: Closed
https://clinicaltrials.gov/study/NCT05642442?term=jzp385-202&rank=1
Inhibikase
IKT-148009-201Brief summary: This study investigates the safety and tolerability of drug IkT-148009 in untreated Parkinson's disease volunteers (30 to 80 years old). It also looks at the pharmacokinetics of IkT-148009 in the body and evaluates the effect of IkT-148009 on motor and non-motor features of the disease.
Status: Closed
https://www.clinicaltrials.gov/study/NCT05424276?spons=Inhibikase%20Therapeutics,%20Inc.&rank=2
Support
Our clinical trials enable us to innovate and discover new, effective treatments for Parkinson's disease and other movement disorders. The importance of our work cannot be overstated, as it brings us closer to a cure and improves the quality of life for countless patients. Donations are crucial to sustaining this vital research and ensuring ongoing progress.
To support our mission, click here or reach out to Ashley Messer at amesser2@usf.edu or (813) 389-2845.